Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17199627 | 0.99 | BTK (0.78) | BTKSYK | |
| SCHEMBL17187799 | 0.91 | BTK (0.72) | BTKSYK | |
| SCHEMBL18761820 | 0.91 | BTK (0.72) | BTKSYK | |
| SCHEMBL18761923 | 0.91 | BTK (0.72) | BTKSYK | |
| SCHEMBL18761807 | 0.90 | BTK (0.71) | BTKSYK | |
| SCHEMBL18761806 | 0.90 | BTK (0.71) | BTKSYK | |
| Ammonia Solution, Strong SCHEMBL20957598 | 0.89 | BTK (0.70) | BTKSYK | |
| Hydrochloric Acid SCHEMBL18761899 | 0.89 | BTK (0.69) | BTKSYK | |
| SCHEMBL17199568 | 0.87 | BTK (0.67) | BTKSYK | |
| SCHEMBL17199607 | 0.87 | BTK (1.00) | BTKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC (US) | 2019-05-09 | — | — | US | claimed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | claimed |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10280184-B2 | Heterocyclic kinase inhibitors | ABBVIE INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280184-B2 | Heterocyclic kinase inhibitors | ABBVIE INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2015158283-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280184-B2 | Heterocyclic kinase inhibitors | MAP3K1, MAP3K20, MAP3K19 | BTK 78/4885SYK 482/4885 |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | BTK 78/4885SYK 482/4885 |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | BTK 81/4885SYK 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.